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October 2Purpose: To evaluate the very long-term results of the randomized Post Operative Radiation Therapy in Endome-
trial Carcinoma (PORTEC)-1 trial for patients with Stage I endometrial carcinoma (EC), focusing on the role of
prognostic factors for treatment selection and the long-term risk of second cancers.
Patients andMethods: The PORTEC trial (1990–1997) included 714 patients with Stage IC Grade 1–2 or Stage IB
Grade 2–3 EC. After surgery, patients were randomly allocated to external-beam pelvic radiotherapy (EBRT) or
no additional treatment (NAT). Analysis was by intention to treat.
Results: 426 patients were alive at the date of analysis. The median follow-up time was 13.3 years. The 15-year
actuarial locoregional recurrence (LRR) rates were 6% for EBRT vs. 15.5% for NAT (p < 0.0001). The 15-year
overall survival was 52% vs. 60% (p = 0.14), and the failure-free survival was 50% vs. 54% (p = 0.94). For patients
with high-intermediate risk criteria, the 15-year overall survival was 41% vs. 48% (p = 0.51), and the 15-year EC-
related death was 14% vs. 13%. Most LRR in the NAT group were vaginal recurrences (11.0% of 15.5%). The 15-
year rates of distant metastases were 9% vs. 7% (p = 0.25). Second primary cancers had been diagnosed over 15
years in 19% of all patients, 22% vs. 16% for EBRT vs. NAT (p = 0.10), with observed vs. expected ratios of 1.6
(EBRT) and 1.2 (NAT) compared with a matched population (p = NS). Multivariate analysis confirmed the prog-
nostic significance of Grade 3 for LRR (hazard ratio [HR] 3.4, p = 0.0003) and for EC death (HR 7.3, p < 0.0001), of
age >60 (HR 3.9, p = 0.002 for LRR and 2.7, p = 0.01 for EC death) andmyometrial invasion >50% (HR 1.9, p = 0.03
and HR 1.9, p = 0.02).
Conclusions: The 15-year outcomes of PORTEC-1 confirm the relevance of HIR criteria for treatment selection,
and a trend for long-term risk of second cancers. EBRT should be avoided in patients with low- and
intermediate-risk EC.
 2011 Elsevier Inc. Open access under the Elsevier OA license.Endometrial carcinoma, Long-term outcome, Randomized trial, Radiation therapy, Prognostic factors.INTRODUCTION
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e631pelvic external-beamRT (EBRT) provides a highly significant
improvement in local control, butwithout a survival advantage
(1–4). The majority (75%) of the locoregional (vaginal and/or
pelvic) recurrences were located in the vagina, and treatment
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were poor (5). EBRT was associated with a 26% risk of side
effects, mainly Grade 1–2 gastrointestinal (GI) toxicity (6).
As a result of these trials, the indication for EBRT has
become limited to patients at a relatively high risk of
recurrence. Risk factors have been identified: Grade 3,
age 60 years or older, and deep myometrial invasion.
Patients with at least two of these three risk factors have
been designated as high-intermediate-risk (HIR). Patients
with HIR features have a 20% risk of locoregional recur-
rence (LRR) after no additional treatment (NAT), which
is reduced to 5% with EBRT. For these HIR patients, the
indication for RT has been maintained after PORTEC-1,
and EBRT was abandoned for the 55% patients with Stage
I EC who were designated as low to intermediate risk
(LIR).
In theGynecologyOncologyGroup (GOG) 99 trial, which
included patientswith Stage I–IIAEC after surgery including
lymphadenectomy (LA) with negative nodes, a similar HIR
groupwas identified (3). EBRT resulted in a hazard reduction
of 58% for both LIR and HIR, but this reduction was clini-
cally relevant only in theHIRgroup. The 4-year isolated local
relapse rate was reduced from 13% to 5% in the HIR group
(3). These results were essentially the same as those from
PORTEC-1, showing that both with and without LA, the
risk factors Grade 3, deep invasion, older age, and lympho-
vascular space invasion are associated with local recurrence.
The subsequent randomized PORTEC-2 trial for Interna-
tional Federation of Gynecology and Obstetrics (FIGO)
1988 Stage I–-IIA EC patients with HIR factors confirmed
that EBRT could safely be substituted by vaginal brachyther-
apy (VBT), with less toxicity and better quality of life (7, 8).
However, for high-risk EC—FIGO 2009 (9) Stages IB Grade
3, II, III; or Stages IB–III with serous/clear cell histology—
EBRT continues to be the most effective adjuvant treatment
for pelvic control (10–12).
The present analysis was done to evaluate very long-term
outcomes of the PORTEC-1 trial, to investigate whether
patients with HIR EC benefited more from EBRT than those
without HIR factors, and to analyze the long-term risk of
second cancers.PATIENTS AND METHODS
Patient selection and treatment
The PORTEC-1 trial was a multicenter trial accruing during
1990 to 1997. The details of patient evaluation and treatment
have been described in previous publications (2, 6). Surgery
consisted of total extrafascial hysterectomy and bilateral
salpingo-oophorectomy without LA (only biopsy of any suspi-
cious lymph nodes). Women of any age, World Health Organiza-
tion performance score 0–2, with endometrial adenocarcinoma
Stage I, Grade 1 with deep (50%) myometrial invasion, Grade 2
with any invasion, or Grade 3 with superficial (<50%) invasion
were eligible. The protocol was approved by the Protocol Review
Committee of the Dutch Cancer Society and by the ethics commit-
tees of the Daniel den Hoed Cancer Center and of the participating
centers.Radiation therapy
Pelvic EBRTwas administeredwith a target volume that included
the parametrial tissues, the proximal two thirds of the vagina, and
lymphatic drainage regions along the internal iliac vessels up to
the promontory. The superior field border was at the L5–S1 disc.
The total dosewas 46Gy in 2-Gy daily fractions. The PORTEC trial
was done before three-dimensional conformal treatment planning
techniques had been introduced. Radiation was delivered by antero-
posterior–posteroanterior parallel opposed fields (30%), by use of
three-field (18%) or four-field techniques (52%), with calculation
of the dose distribution on the central axis and specification at iso-
center or midplane (6).
Pathology review
Central pathology review was done after patient inclusion (13).
Histopathologic slides of 567 patients (79%) were obtained. The
diagnosis of endometrial carcinoma was confirmed in all patients.
The histologic grade was determined at review according to the
FIGO 1988 grading criteria (14, 15). Systematic grading according
to these criteria led to the assignment of Grade 1 to significantly
more tumors: 60% of the tumors were Grade 1, 32% were Grade 2,
and 8% were Grade 3, in contrast to the initial assignment of 21%
Grade 1, 68% Grade 2, and 11% Grade 3. The outcomes in patients
with Grade 1 or 2 tumors were similar, in contrast to Grade 3 (13).
In the present analysis, histologic grades determined at review were
used. In cases without pathology review the grade was assigned not
done.’’ For determination of HIR and LIR groups, patients with re-
view grade ‘‘not done’’’ were assigned Grade 2.
Follow-up
Patients were followed up in their regional hospitals until at least
7 years after treatment. The LRR were confirmed by histology.
LRR was defined as vaginal and/or pelvic recurrence. Distant fail-
ures included paraaortic lymph node metastases; abdominal
relapses; liver, lung, and bone metastases; and diffuse metastatic
disease.
For the present analysis, the vital status of all patients considered
to be alive and disease free according to the trial database was
checked with the Dutch Bureau for Genealogy and/or the govern-
mental local population administration.
The analysis of long-term health-related quality of life (HRQL)
has been addressed in a separate publication (16). The current anal-
ysis was done to evaluate prognostic factors, to establish the role of
HIR factors for treatment selection, and to evaluate the long-term
risk of second cancers after EBRT.
Statistical methods
The primary endpoints for the study were LRR and overall sur-
vival (OS). The secondary endpoints were morbidity and survival
after relapse.
The analysis was by intention to treat. All randomized patients
were kept in the analysis, including thosewho did notmeet eligibility
criteria (n = 10) and those with protocol violations (n = 31). The
Kaplan-Meier method, log-rank test, and Cox regression analysis
were used for time-to-event analyses (2, 5). Competing risk
probabilities of failure were calculated with the following
competing risks of first failure type: LRR, distant metastasis, and
death without relapse. If metastases were detected together with
LRR, the failure type was metastases. Competing risk analysis was
also applied to calculate probabilities of risk of death split by cause
of death, and LRR split by type (vaginal or pelvic). Combined
vaginal and pelvic recurrences were scored as pelvic recurrence.
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compared with the expected numbers based on Dutch sex- and
age-specific incidence rates of cancer and death (17), using the
subject-years method.
Prognostic factors considered in the analysiswere as follows: age,
depth of myometrial invasion, and (review) grade. Age (at random-
ization) was classified a priori in three groups: <60, 60–70, and >70
years. Differences between the treatment groups in risk of relapse or
deathwere testedwith the log-rank test without adjustment for prog-
nostic factors, and with the likelihood ratio test in Cox regression
analysis with adjustment. All reported p values are based on two-
sided tests with p values <0.05 considered statistically significant.RESULTS
Outcomes
A total of 715 eligible patients with Stage I EC were
enrolled; 354 patients were randomly assigned to EBRT,
and 361 to NAT. One patient was excluded because all infor-
mation was irretrievably missing. Thus, 714 patients were
evaluated. The study groups were well balanced with regard
to patient and tumor characteristics (Table 1).
The present analysis was done on data frozen on March 1,
2009. Forty-eight patients were lost to follow-up (41 of
whomwere lost after >5 years’ follow-up); theywere includedTable 1. Patient characteristics after central pathology
review
Characteristic
No. of patients (%)
RT (n = 354) NAT (n = 360)
Age (y)
<60 93 (26) 108 (30)
60–70 136 (38) 134 (37)
>70 125 (35) 118 (33)
Mean (SD) 66.3 (SD 9) 65.7 (SD 9)
Range 41–85 43–90
Myometrial invasion
<50% 138 (39) 156 (43)
$50% 216 (61) 204 (57)
Revised histologic grade
1 198 (56) 197 (55)
2 49 (14) 39 (11)
3 32 (09) 54 (15)
ND* 75 (21) 70 (19)
Revised FIGO 1988 stage
IB Grade 1y 60 (17) 74 (21)
IB Grade 2z 56 (16) 47 (13)
IB Grade 3 22 (06) 35 (10)
IC Grade 1 138 (39) 123 (34)
IC Grade 2z 68 (19) 62 (17)
IC Grade 3 10 (03) 19 (05)
Vascular space invasion
Present 22 (06) 19 (05)
HIR
No 170 (48) 178 (49)
Yes 184 (52) 182 (51)
Abbreviations: RT = radiotherapy; NAT = no additional treat-
ment; SD = standard deviation; FIGO = International Federation
of Gynecology and Obstetrics; HIR = high to intermediate risk.
* ND = no review grade.
y Ineligible at review.
z Includes ND grade.in the analysis and censored at the date of last follow-up. The
median follow-up for patients alivewas 13.3years (range, 2.8–
18.5 years).
Table 2 shows the 15-year rates of LRR, metastases, OS,
and failure-free survival (FFS) by treatment group. The
15-year LRR rates were 5.8% in the RT group and 15.5%
in the NAT group (hazard ratio [HR] for NAT 3.46; 95%
CI 1.93–6.18; log-rank test p < 0.0001). For comparison,
the 5-year, 10-year, and 15-year LRR rates were 4.2% vs.
13.7% (2); 4.6% vs. 14.3% (13), and 5.8% vs. 15.5%.
Among 50 LRR in the NAT arm, 37 (74%) were located in
the vagina. The 15-year rates of distant metastases were sim-
ilar in the treatment groups: 9.3% for EBRT and 7.1% for
NAT (p = 0.25).
In both treatment arms, some very late recurrences were
diagnosed (Fig. 1). All late recurrences were histologically
confirmed, showing adenocarcinoma similar to the previous
endometrial carcinoma. In 1 patient in the RT group, a large
(6-cm) abdominal recurrence was diagnosed 16 years after
treatment. The patient was given hormonal therapy and at
this writing is alive with partial remission. In 2 patients in
the NAT group, vaginal recurrence and vaginal and pelvic
recurrences were found after 9 and 14 years, respectively.
These patients were treated with EBRT and at this writing
are without evidence of disease.
A total of 288 patients had died: 67 as a result of EC (13
pelvic disease, 47 metastases, 1 related to primary treatment,Table 2. Long-term outcomes at 15 years (actuarial
probabilities) by treatment arm
Outcome
RT (n = 354) NAT (n = 360)
Events
15-year
% (SE) Events
15-year
% (SE)
Survival
Alive 202 52% (3) 224 60% (3)
Death EC 37 11% (2) 30 8% (1)
Death other causes 115 38% (3) 106 31% (3)
Survival: HIR
Alive 85 41% (4) 93 48% (4)
Death EC 25 14% (3) 24 13% (3)
Death other causes 74 45% (4) 65 39% (4)
Recurrence
Vaginal 8 2.5% (0.6) 37 11.0% (1.3)
Pelvic 7 3.4% (1.6) 13 4.5% (1.4)
Distant 32 9.3% (1.6) 24 7.1% (1.4)
First failure
No failure 198 50.1% (3.3) 203 54.4% (3.0)
Death NED 115 38.1% (3.2) 94 27.7% (3.0)
Vaginal recurrence 8 2.3% (0.8) 37 10.3% (1.6)
Pelvic recurrence 7 2.5% (1.0) 13 4.0% (1.1)
Distant recurrence 26 7.1% (1.4) 13 3.6% (1.0)
Second cancer
Breast 11 4.8% (1.6) 18 6.6% (1.6)
GI 19 6.2% (1.4) 10 3.2% (1.0)
Other 25 10.6% (2.3) 14 6.0% (1.7)
Abbreviations: RT = radiotherapy; NAT = no additional treat-
ment; EC = endometrial carcinoma; NED = no evidence of disease;
HIR = high to intermediate risk; GI = gastrointestinal; SE = stan-
dard error.
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Fig. 1. Probability of locoregional (vaginal and/or pelvic) relapse for patients assigned to postoperative radiotherapy (RT)
or no additional treatment (NAT) for the total group (left) and for patients with high-intermediate-risk (HIR) features
(right).
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but with previous diagnosis of relapse) and 221 of other
causes (51 second cancers, 165 intercurrent diseases, 5
unknown). The OS rates were 81% vs. 85% at 5 years (2),
68% vs. 74% at 10 years, and 52% vs. 60% at 15 years
(p = 0.14). For patients with HIR features, the OS rates at
10 and 15 years were 60% vs. 64% and 41% vs. 48%, respec-
tively (p = 0.35). The rates of death were compared with
those of an age-matched population. The observed vs.
expected ratios were 1.14 for the total group: 1.22 in the
EBRT group vs. 1.06 in the NAT group (p = NS).
In Fig. 2 the FFS rates by treatment group are shown for
all patients and for those with HIR features. The FFS at 15
years was 50% vs. 54% (p = 0.94), and among HIR patients
FFS was nonsignificantly slightly higher in the EBRT
group.TR
TR on
knargoL
N
453
063
F
651
751
49.0= P
TR
TR on
:ksir tA
453
063
282
472
922
722
95
16
TR
TR on
0
52
05
57
001
sraey0 5 01 51
Cu
m
ul
at
ive
 p
er
ce
nt
ag
e
mra tnemtaerT
lla - lavivrus eerf eruliaF
Fig. 2. Probability of failure-free survival for patients assigned
ment (NAT) for the total group (left) and for patients with highSurvival after recurrence
The 5- and 10-year survival rates after recurrence were
significantly better in the NAT group: 48% (NAT) vs. 12%
(EBRT) at 5 years and 35% vs. 7% at 10 years (p < 0.01).
The survival rates after vaginal recurrencewere 70% (NAT)
vs. 38% (EBRT) at 5 years and 51% vs. 25% at 10 years. The
estimated 10-year survival rates for NAT vs. EBRTwere 18%
vs. 0% for pelvic relapse and 8% vs. 4% for distant relapse.
Three patients with distant metastases were still alive and
progression-free after 14, 12, and 10 years: 2 after surgical
excision of a solitary pulmonary metastasis and a solitary
omental metastasis, respectively; the third after salvage RT
for vaginal recurrence and prolonged complete response
during hormonal treatment of histologically verified pulmo-
nary metastasis which had occurred 3 years after vaginal
recurrence.TR
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to postoperative radiotherapy (RT) or no additional treat-
-intermediate-risk (HIR) features (right).
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Second cancers were diagnosed in 97 patients, with
15-year rates of 22% in the EBRT group vs. 16% in the
NAT group (p = 0.10). The incidence rates were compared
with those of an age-and sex-matched population: the ob-
served vs. expected ratios were 1.40 for the total group:
1.62 for EBRT and 1.20 for NAT (p = NS).
Second cancer types were breast cancer (6% at 15 years),
cancers of the GI tract (5%), and various other types (8%).
The predominant cancer type among EBRT patients was
GI cancer (6.2% vs. 3.2% among NAT patients), and breast
cancer was most frequent in the NAT group (6.6% vs. 4.8%
in the EBRT group). These differences did not reach statis-
tical significance (p = 0.10).Prognostic factors
Table 3 shows multivariate analysis of prognostic factors
for LRR and EC-related death. The HR for LRR, adjusted
for major prognostic factors, were 3.46 for NAT compared
to EBRT (p < 0.0001), 3.35 for review Grade 3 (p < 0.001)
and 1.66 for Grade 2 (p = 0.19) as compared to Grade 1;
and 3.90 for age 60 years compared to <60 years (p =
0.0017). Figure 3 shows OS split by prognostic factors.
The risk of EC-related death was significantly higher for
patients $60 years and especially for patients with Grade
3 tumors (HR 7.3, p < 0.0001). After adjustment for age,
grade, and invasion there was no evidence of benefit of
EBRT for OS or EC-specific survival.DISCUSSION
The recent publication of the results of the ASTEC trial
included a meta-analysis of the ASTEC, GOG 99, and
PORTEC-1 trials, which excluded a survival benefit of
EBRT in intermediate-risk endometrial cancer of more
than 3% (4). Moreover, the results of previous meta-
analyses suggested that EBRT may even be harmful for
patients with features of low to intermediate risk, given
that these patients have a low risk of recurrence after surgery
alone, and EBRT adds toxicity and risks without improving
survival (18, 19). This was confirmed in the current analysis,
with results showing a trend for lower OS after EBRT,Table 3. Cox regre
Variable
Locoregional relapse
HR 95% CI p value
NAT arm 3.46 1.93 –6.18 <0.0001
Age $60 y 3.90 1.67–9.11 0.0017
Review Grade 2 1.66 0.78–3.52 0.19
Review Grade 3 3.35 1.75–6.41 0.0003
Invasion >50% 1.86 1.07–3.24 0.027
HIR patients
NAT arm 3.31 1.73–6.35 0.0003
Review Grade 2 1.53 0.62–3.79 0.35
Review Grade 3 2.15 1.10–4.21 0.026
Abbreviations: HR = hazard ratio; NAT = no additional treatment; CIwhereas the FFS curves overlapped. However, for patients
with HIR features, the OS rates were similar, and FFS was
slightly (but nonsignificantly) higher after EBRT.
The abandonment of EBRT for patients with LIR features
has been confirmed to be a correct decision. EBRT causes
side effects (6) and has been shown in our recent analysis
to have a very long-term negative impact on HRQL (16).
Moreover, we found a trend toward more second cancers
among EBRT patients, especially cancers of the GI tract.
EBRT can therefore not be justified in the absence of sur-
vival benefit and in the presence of effective salvage RT
for the very few LIR patients who develop locoregional
recurrence. Although current sophisticated EBRT planning
techniques (intensity-modulated RT) may be expected to
have lower GI toxicity rates (20), the irradiated volume in
the lower pelvis remains large, and the long-term risks of
pelvic floor dysfunction, GI symptoms, and second cancers
cannot be disregarded.
For patients with HIR features, the indication for RT was
maintained because their 5-year risk of LRR was 20%,
which was considered sufficiently high to justify adjuvant
treatment significantly improving local control. For these
patients, the subsequent PORTEC-2 trial showed that VBT
was highly effective, with fewer side effects and better
HRQL than after EBRT (8). Patients who received VBT
did not have the increased bowel symptoms reported by
EBRT patients, most notably diarrhea, urgency, and higher
need to remain close to a toilet (7). As a result of the
PORTEC-2 trial, patients with HIR EC are currently treated
with VBT.
External-beam RT has remained indicated only for the
15% of EC patients with high-risk features (Grade 3 with
deep invasion and/or lymph-vascular space invasion
(LVSI), serous or clear cell histology) or advanced stages.
Omitting EBRT for those patients has been shown to result
in significantly lower pelvic control rates and may even af-
fect survival (10, 12). The use of high-risk and HIR factors
for decisions on adjuvant treatment underlines the critical
importance of complete and reproducible pathology evalua-
tion in the treatment of EC patients.
Adjuvant chemotherapy might be considered in view of
the higher risk of distant metastases among patients withssion analysis
Death related to endometrial cancer
HR 95% CI p value
0.71 0.43–1.16 0.17
2.66 1.26–5.61 0.010
2.20 1.07– 4.51 0.032
7.30 3.94–13.53 <0.0001
1.86 1.09–3.17 0.024
0.87 0.50–1.50 0.61
1.93 0.81–4.60 0.14
4.31 2.28–8.12 <0.0001
= confidence interval; HIR= high to intermediate risk.
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Fig. 3. Probability of overall survival according to prognostic factors: depth of myometrial invasion (<50% vs. $50%,
top left), patient age (<60 vs. 60–70 vs. >70 years, top right), revised International Federation of Gynecology and Obstet-
rics (FIGO) Grade (1 vs. 2 vs. 3 vs. ND grade, bottom left), and presence vs. absence of high-intermediate-risk (HIR)
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e636 I. J. Radiation Oncology d Biology d Physics Volume 81, Number 4, 2011high-risk EC. Although two randomized trials comparing
chemotherapy alone with pelvic EBRT alone did not show
differences in OS, progression-free survival, or relapse rates
(21, 22), the Nordic Society of Gynaecological Oncology/
European Organisation for the Research and Treatment of
Cancer (NSGO9501/EORTC55991) trial comparing EBRT
alone with EBRT preceded or followed by chemotherapy
showed a 7% increase in progression-free survival (p =
0.03) and a trend for improved OS (p = 0.08) in the combined
EBRT + chemotherapy arm (23). The current international
randomized PORTEC-3 trial for patients with high-risk
and advanced-stage EC investigates the survival benefit, tox-
icities, and impact on quality of life of EBRT + chemother-
apy compared with EBRTalone. Both treatments are started
early (two cycles of cisplatin during EBRTand four cycles of
carboplatin and paclitaxel after the completion of EBRT),
which obviates the need to decide which treatment should
be given first (24). Two current ongoing GOG trials (GOG249 and 258) investigate the role of chemotherapy for
early-stage HIR and high-risk EC (three cycles of carbopla-
tin and paclitaxel and VBT vs. EBRT), and advanced-stage
EC (EBRT plus two cycles of cisplatin followed by four cy-
cles of carboplatin and paclitaxel vs. six cycles of carbopla-
tin and paclitaxel), respectively.
The PORTEC-1 and -2, GOG 99, and ASTEC trials (2–4,
8) have resulted in a significant reduction of the treatment
burden for a large number of patients with endometrial
carcinoma, abandoning EBRT for 85% of EC patients and
introducing VBT as adjuvant treatment for the 30% of EC
patients with HIR features. It should be noted that the
favorable results in the control arm of PORTEC-1 and in
the VBT arm of PORTEC-2 were obtained in the absence
of LA, whereas only 30% of patients in the ASTEC trial
underwent LA. These results were very similar to those of
GOG 99 (3), which required LA and included only patients
who were node negative. Two recent large randomized trials
15-year outcomes of the PORTEC-1 trial d C. L. CREUTZBERG et al. e637investigated the role of LA and did not find a survival benefit
or any differences in patterns and sites of relapse (25, 26).
The Italian trial (26), which had a median node count of
23 to 30 in the LA arm, showed identical rates of vaginal re-
currence (2.6% for LA vs. 2.4% for no LA), lymph node re-
currence (1.5% vs. 1.6%), and intraperitoneal relapse (3%
vs. 2.8%) in both arms. The abandonment of EBRT for
85% of EC patients should thus not encourage the increased
use of LA to identify the 9% of patients with microscopic
node metastases. This will not affect their survival and add
morbidity: 18.6% vs. 8.8% risk of late complications for
LA vs. no LA, most notably 10.2% vs. 1.6% lymphedema
(26, 27). Lymphedema has been shown to affect HRQL,
and women with LA reported more clinically relevant
edema symptoms (25.6 vs. 16.9, p < 0.001) (28). Powerfulprognostic factors, especially Grade 3 (with HR of 7.3 for
EC death in the current analysis), and lymphovascular space
invasion (29, 30), are available at histologic examination and
are associated with increased risk of distant spread. These
factors can be used to select patients who might benefit
from systemic treatments reaching areas that neither
radiation nor the surgical knife can effectively treat.
In conclusion, the 15-year results of the PORTEC-1 trial
have confirmed the highly significant improvement of local
control obtained by EBRT but an absence of survival benefit.
HIR features were shown to be useful for selection for RT
(currently VBT). In view of the long-term negative impact
of EBRT, the absence of survival benefit, and the presence
of effective salvage treatment, the rationale for the abandon-
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